Laboratory diagnosis of congenital von Willebrand disease

被引:67
作者
Budde, U
Drewke, E
Mainusch, K
Schneppenheim, R
机构
[1] Lab Assoc Prof Arndt & Partners, Coagulat Lab, D-22339 Hamburg, Germany
[2] Univ Clin, Childrens Hosp, Dept Hematol, Hamburg, Germany
关键词
vWD; von Willebrand factor; classification; ristocetin cofactor assay; von Willebrand collagen binding capacity assay; vWF multimers; standardization;
D O I
10.1055/s-2002-27820
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
von Willebrand disease (vWD) is caused by quantitative or qualitative defects, or both, of the von Willebrand factor (vWF), a multimeric high-molecular glycoprotein (GP). Typically, it affects the primary hemostatic system, which is reflected by a mucocutaneous bleeding tendency simulating a platelet function defect. The vWF promotes its function in two ways: (1) by supporting platelet adhesion to the injured vessel wall under conditions of high shear forces and (2) by its carrier function for factor VIIIc (FVIIIc) in plasma. Because of the complexity of the disease, diagnosis of vWD is one of the most challenging of any coagulation disorder. The stepwise diagnosis of vWD includes patients and family history, screening procedures (bleeding time [BT], filter tests, platelet counts, activated partial thromboplastin time [aPTT]), confirmatory, tests (vWF antigen [vWF:Ag], vWF ristocetin cofactor activity [vWF:RCo], vWF collagen-binding [vWF:CB] assay, ristocetin-induced platelet aggregation [RIPA], FVIIIc) and tests for final classification (multimeric analysis, FVIII binding capacity of vWF [vWF:FVIIIB], platelet vWF). In 1999, we classified 303 patients with congenital vWD) as type 1 (n = 122), type 2 (n = 171), and type 3 (n = 10). Type 2 was further subdivided into type 2A (n = 126), type 2B (n = 17), type 2M (n = 22), and type 2M (n = 6). Type 2A showed a remarkable heterogencity with only, 27.8% (n = 36) of the "classic" IIA pattern. The other high-frequency patterns were type IB (25.4% n = 32) and type IIE/F/H-like structural abnormalities (28.6% n = 36). The spectrum was completed with samples from patients with types 2D, 2C, 2C Miami, smeary structures, and other rare subtypes (together 18.9% n = 23).
引用
收藏
页码:173 / 189
页数:17
相关论文
共 123 条
[1]  
AIHARA M, 1986, THROMB HAEMOSTASIS, V55, P263
[2]   Two novel type 2N von Willebrand disease-causing mutations that result in defective factor VIII binding, multimerization, and secretion of von Willebrand factor [J].
Allen, S ;
Abuzenadah, AM ;
Blagg, JL ;
Hinks, J ;
Nesbitt, IM ;
Goodeve, AC ;
Gursel, T ;
Ingerslev, J ;
Peake, IR ;
Daly, ME .
BLOOD, 2000, 95 (06) :2000-2007
[3]   MULTIMERIC ANALYSIS OF VONWILLEBRAND-FACTOR BY VERTICAL SODIUM DODECYL-SULFATE AGAROSE-GEL ELECTROPHORESIS, VACUUM BLOTTING TECHNOLOGY AND SENSITIVE VISUALIZATION BY ALKALINE-PHOSPHATASE ANTIALKALINE PHOSPHATASE COMPLEX [J].
BAILLOD, P ;
AFFOLTER, B ;
KURT, GH ;
PFLUGSHAUPT, R .
THROMBOSIS RESEARCH, 1992, 66 (06) :745-755
[4]   SHEAR RATE DEPENDENT INHIBITION OF PLATELET-ADHESION AND AGGREGATION ON COLLAGENOUS SURFACES BY ANTIBODIES TO HUMAN FACTOR-VIII-VONWILLEBRAND FACTOR [J].
BAUMGARTNER, HR ;
TSCHOPP, TB ;
MEYER, D .
BRITISH JOURNAL OF HAEMATOLOGY, 1980, 44 (01) :127-139
[6]   ASSAY OF WILLEBRAND FACTOR IN VONWILLEBRANDS DISEASE AND HEMOPHILIA - USE OF A MACROSCOPIC PLATELET-AGGREGATION TEST [J].
BRINKHOUS, KM ;
GRAHAM, JE ;
COOPER, HA ;
ALLAIN, JP ;
WAGNER, RH .
THROMBOSIS RESEARCH, 1975, 6 (03) :267-272
[7]   AN ELISA TEST FOR THE BINDING OF VONWILLEBRAND ANTIGEN TO COLLAGEN [J].
BROWN, JE ;
BOSAK, JO .
THROMBOSIS RESEARCH, 1986, 43 (03) :303-311
[8]  
BUDDE U, 1993, BLOOD, V82, P1749
[9]  
BUDDE U, 1990, THROMB HAEMOSTASIS, V63, P312
[10]  
BUDDE U, 1986, BLOOD, V68, P1213